Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation (Q43061683)

13 November 2017

title

Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation (English)

1 reference

13 November 2017

Lawrence U Liu

1

1 reference

13 November 2017

Thomas D Schiano

series ordinal

2

1 reference

13 November 2017

publication date

1 March 2007

1 reference

Expert Review of Clinical Immunology

13 November 2017

published in

1 reference

13 November 2017

volume

3

1 reference

13 November 2017

issue

2

1 reference

13 November 2017

page(s)

125-130

1 reference

Passive-active immunoprophylaxis after percutaneous exposure to hepatitis B virus

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Vaccination of chimpanzees against infection by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Hepatitis C virus kinetics during and immediately after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/1744666X.3.2.125

21 January 2018

Identifiers

DOI

10.1586/1744666X.3.2.125

1 reference

13 November 2017

1 reference